You are here

Symptoms of Differentiation Syndrome Going Unrecognized with Idhifa

Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia

The FDA has warned that signs and symptoms of differentiation syndrome are not being recognized in patients receiving Idhifa (enasidenib, Celgene), a medicine for acute myeloid leukemia (AML). Although the drug’s prescribing information contains a warning about the serious side effect, cases are not being recognized and some patients are not receiving the necessary treatment.

Patients should be made aware of the symptoms of differentiation syndrome when they start enasidenib and at follow-up visits. Differentiation syndrome can occur as early as 10 days and up to five months after starting enasidenib. Symptoms include fever, cough, shortness of breath, swelling of arms and legs, swelling around the neck, groin, or underarm area, fast weight gain of more than 10 pounds within a week, bone pain, and dizziness or lightheadedness.

Enasidenib was approved in August 2017 for patients with AML with the genetic mutation isocitrate dehydrogenase (IDH)-2 whose disease has come back or has not improved after other chemotherapy. Idhifa works by blocking several enzymes that promote the abnormal growth of white blood cells in the bone marrow.

Prior to the drug’s approval, differentiation syndrome had been associated only with induction chemotherapy in patients with a rare form of cancer called acute promyelocytic leukemia. However, a safety report issued by the manufacturer earlier this year cited five deaths in patients taking enasidenib.

Tibsovo (ivosidenib), another recently approved drug for AML with the specific genetic mutation isocitrate dehydrogenase (IDH)-1, also carries a risk of differentiation syndrome. Health care professionals are advised to be vigilant about monitoring for the side effect when they prescribe ivosidenib.

Source:, November 28, 2018

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Nexus Has Increased Power, RF Capabilities